{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ranibizumab",
    "query": {
      "intervention": "ranibizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 262,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ranibizumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T23:42:46.910Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04704921",
      "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "AMD",
        "nAMD",
        "Wet Age-related Macular Degeneration",
        "wAMD",
        "Wet AMD",
        "CNV",
        "Neovascular AMD",
        "Neovascular Age-related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "ABBV-RGX-314",
          "type": "GENETIC"
        },
        {
          "name": "Ranibizumab (LUCENTIS®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 671,
      "start_date": "2020-12-29",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 89,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704921"
    },
    {
      "nct_id": "NCT02358889",
      "title": "Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "hI-con1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Iconic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2015-02",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02358889"
    },
    {
      "nct_id": "NCT01542866",
      "title": "A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age Related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Health Management Tool (HMT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 160,
      "start_date": "2011-01-11",
      "completion_date": "2011-11-30",
      "has_results": false,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 23,
      "location_summary": "Beverly Hills, California • Sacramento, California • Torrance, California + 20 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01542866"
    },
    {
      "nct_id": "NCT05110209",
      "title": "Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "OTHER"
        },
        {
          "name": "Ranibizumab",
          "type": "OTHER"
        },
        {
          "name": "Bevacizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 331541,
      "start_date": "2020-07-15",
      "completion_date": "2020-11-20",
      "has_results": false,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05110209"
    },
    {
      "nct_id": "NCT00804934",
      "title": "Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Wet AMD"
      ],
      "interventions": [
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Institute of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2008-02",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2012-05-28",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00804934"
    },
    {
      "nct_id": "NCT05146687",
      "title": "Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "OTHER"
        },
        {
          "name": "Ranibizumab",
          "type": "OTHER"
        },
        {
          "name": "Bevacizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 369600,
      "start_date": "2020-07-15",
      "completion_date": "2020-12-11",
      "has_results": false,
      "last_update_posted_date": "2021-12-16",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05146687"
    },
    {
      "nct_id": "NCT01334879",
      "title": "High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiation Retinopathy"
      ],
      "interventions": [
        {
          "name": "ranibizumab 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The New York Eye Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-05",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-10-02",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01334879"
    },
    {
      "nct_id": "NCT01581151",
      "title": "Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Dexamethasone intravitreal implant",
          "type": "DRUG"
        },
        {
          "name": "Monthly Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brian Burke, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-09",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-02-20",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01581151"
    },
    {
      "nct_id": "NCT02420132",
      "title": "Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Edema",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2015-04-20",
      "completion_date": "2016-08-25",
      "has_results": false,
      "last_update_posted_date": "2019-06-10",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420132"
    },
    {
      "nct_id": "NCT02355028",
      "title": "LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exudative Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "LHA510 ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "LHA510 vehicle",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon, a Novartis Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 136,
      "start_date": "2015-03-03",
      "completion_date": "2016-10-18",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-09-04T23:42:46.910Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02355028"
    }
  ]
}